SG11201805527QA - Composition for reducing the frequency of urination, method of making and use thereof - Google Patents

Composition for reducing the frequency of urination, method of making and use thereof

Info

Publication number
SG11201805527QA
SG11201805527QA SG11201805527QA SG11201805527QA SG11201805527QA SG 11201805527Q A SG11201805527Q A SG 11201805527QA SG 11201805527Q A SG11201805527Q A SG 11201805527QA SG 11201805527Q A SG11201805527Q A SG 11201805527QA SG 11201805527Q A SG11201805527Q A SG 11201805527QA
Authority
SG
Singapore
Prior art keywords
international
pct
urination
frequency
reducing
Prior art date
Application number
SG11201805527QA
Inventor
David Dill
Original Assignee
Wellesley Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/870,676 external-priority patent/US10596127B2/en
Application filed by Wellesley Pharmaceuticals Llc filed Critical Wellesley Pharmaceuticals Llc
Publication of SG11201805527QA publication Critical patent/SG11201805527QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization IIIMIOH0110101011111 HO 11111 0101111110111110111110011111110111011# International Bureau ... ...... (10) International Publication Number (43) International Publication Date ..... .....\" WO 2017/058436 Al 6 April 2017 (06.04.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/19 (2006.01) A61P 7/12 (2006.01) kind A61K 31/192 (2006.01) A61P 7/00 (2006.01) AO, BZ, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2016/049246 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, 29 August 2016 (29.08.2016) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 14/870,676 30 September 2015 (30.09.2015) US kind GM, of regional protection available): ARIPO (BW, GH, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: WELLESLEY PHARMACEUTICALS, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) LLC [US/US]; 3 Valley View Drive, Newtown, PA 18940 TJ, (US). DK, LV, Inventor: DILL, David, A.; 3 Valley View Drive, New TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, town, PA 18940 (US). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (74) Agent: WANG, Ping, M. D.; Andrews Kurth, LLP, 1350 I Street, N.W. Suite 1100, Washington, DC 20005 (US). Published: — with international search report (Art. 21(3)) (54) Title: COMPOSITION FOR REDUCING THE FREQUENCY OF URINATION, METHOD OF MAKING AND USE THEREOF (57) : A method for manufacturing a pharmaceutical composition for reducing the frequency of urination is dis - NSA! D alone closed. The pharmaceutical composition comprises (1) an an- algesic agent and (2) an a-blocker, a 5a-reductase inhibitor or 0 3 -ci-t- both. 111 z 3 --o--atwetaminophoo 4, ,n m 17 -' ° a) ..c 250 - V ;,.., —E.—Aspirin t JIB thoproten 8 - no - 5 0 ,.. kJ 4- d I 8 ---*-- aproun i CD ° .tt U O .-- 100 - u ° 4 .., ,..) — e - .4 V; en Dose of NSAID 71' 15000-0.00005 ii,M) Ot kr) 0 IN ,-, © ei FIG. l'A O
SG11201805527QA 2015-09-30 2016-08-29 Composition for reducing the frequency of urination, method of making and use thereof SG11201805527QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/870,676 US10596127B2 (en) 2013-03-14 2015-09-30 Composition for reducing the frequency of urination, method of making and use thereof
PCT/US2016/049246 WO2017058436A1 (en) 2015-09-30 2016-08-29 Composition for reducing the frequency of urination, method of making and use thereof

Publications (1)

Publication Number Publication Date
SG11201805527QA true SG11201805527QA (en) 2018-07-30

Family

ID=58424324

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805527QA SG11201805527QA (en) 2015-09-30 2016-08-29 Composition for reducing the frequency of urination, method of making and use thereof

Country Status (7)

Country Link
EP (1) EP3355877A4 (en)
JP (1) JP2018529710A (en)
KR (1) KR20180066113A (en)
CN (1) CN108430465A (en)
AU (1) AU2016331879A1 (en)
SG (1) SG11201805527QA (en)
WO (1) WO2017058436A1 (en)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395626A (en) * 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
KR100630290B1 (en) * 1998-05-15 2006-09-29 쥬가이 세이야쿠 가부시키가이샤 Regulated release preparations
US20030194428A1 (en) * 2002-04-10 2003-10-16 Miller Frederick H. Process for encapsulating multi-phase, multi-compartment capsules
EP1501517B1 (en) * 2002-04-24 2007-05-02 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
CA2658170A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
KR101479324B1 (en) * 2006-11-09 2015-01-05 오렉시젠 세러퓨틱스 인크. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
US9119878B2 (en) * 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
CN103191430A (en) * 2012-01-04 2013-07-10 韦尔斯利医药有限公司 Sustained release preparation for relieving frequent micturition and application method thereof
CN103191429A (en) * 2012-01-04 2013-07-10 韦尔斯利医药有限公司 Extended release formulation for relieving frequent micturition and application method thereof
AU2012363789B2 (en) * 2012-01-04 2017-04-13 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
MX2014011128A (en) * 2012-03-19 2015-08-10 Wellesley Pharmaceuticals Llc Extended-release formulation for reducing the frequency of urination and method of use thereof.
MY171526A (en) * 2012-07-27 2019-10-16 Wellesley Pharmaceuticals Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
TW201422254A (en) * 2012-11-21 2014-06-16 Ferring Bv Composition for immediate and extended release
BR102013020508B1 (en) * 2013-08-12 2021-01-12 Ems S/A. DOSAGE FORM THAT UNDERSTANDS A 5-ALPHA REDUCTASE STEROID INHIBITOR AND AN ALPHA BLOCKER, PROCESS FOR THE PREPARATION OF A DOSAGE FORM AND USE OF THE DOSAGE FORM

Also Published As

Publication number Publication date
KR20180066113A (en) 2018-06-18
WO2017058436A1 (en) 2017-04-06
CN108430465A (en) 2018-08-21
EP3355877A4 (en) 2019-05-15
EP3355877A1 (en) 2018-08-08
AU2016331879A1 (en) 2018-05-17
JP2018529710A (en) 2018-10-11

Similar Documents

Publication Publication Date Title
CA3015496A1 (en) Voice control of a media playback system
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201906373VA (en) Chemical compounds as inhibitors of interleukin-1 activity
SG11201806588PA (en) Devices and methods for fluid transfer through a placed peripheral intravenous catheter
SG11201804368QA (en) Storage assembly for prosthetic valve
SG11201803906PA (en) Control of cellular redox levels
SG11201909383PA (en) Customizable composite dressings for improved granulation and reduced maceration negative-pressure treatment
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201804710TA (en) Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof
SG11201808337TA (en) Deactivation wipe kit and method of forming and using the same
SG11201805164WA (en) Programmable universal quantum annealing with co-planar waveguide flux qubits
SG11201805072PA (en) Nicotine powder delivery system
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201810765PA (en) Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201805777QA (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
SG11201804100UA (en) Pharmaceutical composition comprising a potent inhibitor of urat1
SG11201811259YA (en) Single payment device for multiple payment accounts